Abbott sales
This article was originally published in The Tan Sheet
Executive Summary
Worldwide sales of nutritional products during the fourth quarter were fueled by the performance of the international division, which posted sales growth of 26.2% to $571 mil., Abbott Labs says in Jan. 23 release. International growth was driven by a 6.6% favorable impact from exchange, "with continued strong growth in Latin American and Asian markets," firm says. Total sales of the division increased 11.2% to $1.19 bil. Revenues for U.S. nutritional products were flat at $616 mil., however, excluding the impact of a co-promotion agreement for Rx drug Synagis, U.S. sales of the unit advanced 11%, Abbott notes. For the year, Abbott's international nutritional products division had sales growth of 18.4% to $2.04 bil., boosting net sales for nutritionals 1.7% to $4.39 bil. U.S. nutritional revenues fell 9.4% to $2.35 bil., reflecting the impact of Synagis...
You may also be interested in...
Scrip M&A Podcast: Which Companies Could Be Acquired Next?
The editorial team from Scrip discusses the M&A potential of various emerging biopharmas, such as Viking, Verona, Altimmune, Xenon and Crinetics.
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
P&G Restores Volume Growth In Beauty, Grooming After Pricing Run
Procter & Gamble reports strong consumer spending in the US and Europe after a 3% increase in product pricing over the past year. Dragging on fiscal third-quarter results, sales of SK-II in China fell 30% for the January-March period, while lower incidence of cough and cold impacted Health Care performance.